Endotrophin as a Marker of Complications in a Type 2 Diabetes Cohort.

Autor:	Tougaard NH; Steno Diabetes Center Copenhagen, Herlev, Denmark., Møller AL; Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.; Nordic Bioscience A/S, Herlev, Denmark., Rønn PF; Steno Diabetes Center Copenhagen, Herlev, Denmark., Hansen TW; Steno Diabetes Center Copenhagen, Herlev, Denmark., Genovese F; Nordic Bioscience A/S, Herlev, Denmark., Karsdal MA; Nordic Bioscience A/S, Herlev, Denmark., Rasmussen DGK; Nordic Bioscience A/S, Herlev, Denmark., Rossing P; Steno Diabetes Center Copenhagen, Herlev, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	Diabetes care [Diabetes Care] 2022 Nov 01; Vol. 45 (11), pp. 2746-2748.
DOI:	10.2337/dc22-0852
Abstrakt:	Objective: We investigated endotrophin, a profibrotic signaling molecule reflecting collagen VI formation, in serum and urine as risk marker for complications to type 2 diabetes. Research Design and Methods: Endotrophin was measured in 774 individuals with type 2 diabetes. Outcomes included a composite kidney end point, first major adverse cardiovascular event (MACE), mortality, progression of albuminuria, incident heart failure, and sight-threatening eye disease. Adjusted Cox proportional hazards models were applied. Results: Doubling of serum endotrophin was associated with the kidney end point (n = 49; hazard ratio 1.80 [95% CI 1.13-2.87]), first MACE (n = 66; 1.54 [1.04-2.28]), mortality (n = 156; 1.69 (1.31-2.19]), and incident heart failure (n = 42; 1.63 [1.02-2.60]). A doubling of urine endotrophin was associated with progression of albuminuria (n = 85; 1.20 [1.04-1.39]). Conclusions: Serum endotrophin was a risk marker for mortality and kidney and cardiovascular complications in type 2 diabetes. Urine endotrophin was a marker for albuminuria progression. (© 2022 by the American Diabetes Association.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu